期刊文献+

拓扑替康不良反应情况调查分析 被引量:1

原文传递
导出
摘要 目的:调查分析拓扑替康不良反应发生情况,为临床合理应用提供参考。方法:通过PubMed数据库,检索2005年6月—2014年3月有关拓扑替康不良反应的文献,并进行统计分析。结果:共检索出拓扑替康不良反应的报道228篇,其中90.5%涉及血液系统,47.6%涉及消化系统,23.8%涉及神经系统,19.0%涉及呼吸系统,4.8%涉及皮肤与其他。结论:拓扑替康的不良反应主要涉及血液、消化、神经、呼吸等系统,应引起临床医务人员的重视。
出处 《人民军医》 2014年第6期660-661,673,共3页 People's Military Surgeon
  • 相关文献

参考文献14

  • 1Acevedo-Gadea C,Santin AD, Higgins SA,et al. Phase I clinical trial of the Mammalian target of rapamycin inhibitor everolimus in combi- nation with oral topotecan for recurrent and advanced endometrial cancer[J]. Int J Gynecol Cancer,2014,24(3) :528-533.
  • 2Di Giannatale A,Dias-Gastellier N,Devos A,et al. Phase Ⅱ study of temozolomide in combination with topoteean(TOTEM)in relapsed or refractory neuroblastoma:A European Innovative Therapies for Chil- dren with Cancer-SIOP-European Neuroblastoma study[J]. Eur J Cancer,2014,50(1) :170-177.
  • 3Bochennek K, Dantonello T, Koscielniak E, et al. Response of children with stage IV soft tissue sarcoma to topotecan and carboplatin: A phase Ⅱ window trial of the cooperative soft tissue sarcoma group [J]. Klin Padiatr,2013,225(6) :309-314.
  • 4yon Gruenigen VE,Frasure HE,Smith DA,et al. Toxicity of weekly oral topoteean in relation to dosage for gynecologic malignancies: a phase I study[J]. Anticancer Drugs, 2012,23 (7) : 724-730.
  • 5Samol J,Ranson M,Scott E,et al. Safety and tolerability of the poly (ADP-ribose) polymerase (PARP) inhibitor, olaparib (AZI32281) in combination with topotecan for the treatment of patients with ad- vanced solid tumors: A phase I study[J]. Invest New Drugs, 2012,30 (4) :1493-1500.
  • 6Kasow KA,Stewart CF,Barfield RC,et al. A phase Ⅰ/Ⅱ study of CY and topotecan in patients with high-risk malignancies undergoing au- tologous hematopoietic cell transplantation: The St Jude long-term follow-up[J]. Bone Marrow Transplant ,2012,47(11) : 1448-1454.
  • 7Mcgonigle KF,Muntz HG,Vuky J,et al. Combined weekly topoteean and biweekly bevacizumab in women with platinum-resistant ovarian, peritoneal,or fallopian tube cancer: results of a phase 2 study [J]. Cancer,2011,117(16) : 3731-3740.
  • 8Kazmi SM,Saliba RM,Donato M,etal. Phase Ⅱ trial of high-dose to- potecan, melphalan and CY With autologous stem cell support for multiple myelorna [J]. Bone Marrow Transplant, 2011, 46 ( 4 ) : 510-515.
  • 9Potter SL,Berg S,Ingle AM,et al. Phase 2 clinical trial of intrathecal topoteean in children with refractory leptomeningeal leukemia: A Children's Oncology Group trial(P9962)[J]. Pediatr Blood Cancer, 2012,58(3) : 362-365.
  • 10Baka S, Agelaki S, Kotsakis A,et al. Phase Ⅲ study comparing se- quential versus alternate administration of cisplatin-etoposide and to- potecan as first-line treatment in small cell lung cancer[J]. Anticancer Res, 2010,30(7) : 3031-3038.

同被引文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部